The burrito maker's expansion into Asia follows its moves into Mexico and the Mideast. The stock is down 35% year to date and is nearing its lowest level in 10 years. ...

Embraer expects to reach 100 commercial aircraft deliveries per year in 2028, its CEO told Reuters, adding that supply chain issues will likely keep the Brazilian planemaker from hitting that mark soo... ...

As the Securities and Exchange Commission’s (SEC) 75-day review window expires, the crypto exchange-traded funds (ETFs) introduced jointly by REX and Osprey can begin trading on Sep. 12. Bloomberg analyst Eric Balchunas said the funds have been filed under the Investment Company Act of 1940 which "doesn’t directly invest fully in spot." It means as long as the SEC doesn’t object during the review period, "you can let it launch 75 days after filing,” he told Cointelegraph. The package expected to debut to ...

Let's do some final trades here on a pretty big day for stocks. Josh Brown, I mentioned rocket on Tuesday as my final trade. The stock has officially broken out.New 52- week high. Staying long. It looks great.Jimmy did this just just to put his thumb in my eye. That has nothing to do with you. The stock market's getting it wrong on Delta Airlines.Sirat agrees with me. You know, there's always a I feel like there's mot extra motivation to this. Do you What do you think, Sat.Listen, I think it's the best run ...

The U.S. stock market surged to fresh record highs in afternoon trading on Thursday, September 11, 2025, buoyed by a combination of favorable inflation data and strong expectations for a Federal Reserve interest rate cut next week. Investors largely shrugged off a mixed jobs report, focusing instead on the broader narrative of easing inflationary pressures and supportive monetary policy. The Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all extended their gains, continuing a robust rally that ...

There’s a lot going on in Idaho these days. And it's no small potatoes. The stock of Boise, Idaho-based Micro Technology (MU) is one of the most intriguing chart-based stock situations I see right now. The maker of high-performance memory and storage technologies is in the sweet spot for growth right now. The stock has mimicked the broader tech sector’s manic 2025 so far, giving up 40% of its value in under 3 weeks in the spring, only to rally 150% since that time. That $60 stock from April is now in the ...

The iShares MSCI Emerging Markets ETF (NYSEARCA: EEM ) has returned more than 24% so far this year. That outpaces the S&P 500 SPDR Trust ETF’s ( SPY ) 12.0% total return and trounces the average U.S. stock’s mere 8% 2025 advance.Freelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passion is putting a narrati ...

The iShares MSCI Emerging Markets ETF (NYSEARCA: EEM ) has returned more than 24% so far this year. That outpaces the S&P 500 SPDR Trust ETF’s ( SPY ) 12.0% total return and trounces the average U.S. stock’s mere 8% 2025 advance.Freelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passion is putting a narrati ...

The FTC announced on Thursday that it is launching an inquiry into seven tech companies that make AI chatbot companion products for minors: Alphabet, CharacterAI, Instagram, Meta, OpenAI, Snap, and xAI.The federal regulator seeks to learn how these companies are evaluating the safety and monetization of chatbot companions, how they try to limit negative impacts on children and teens, and if parents are made aware of potential risks. This technology has proven controversial for its poor outcomes for child u ...

Maze Therapeutics, Inc. MAZE on Thursday shared clinical results from the Phase 1 healthy volunteer study of MZE782, an oral small molecule targeting the solute transporter, SLC6A19.MZE782 has the potential to be a best-in-class therapy for patients with phenylketonuria (PKU), an inherited metabolic disorder, and a first-in-class therapy for chronic kidney disease (CKD).MAZE is reaching significant price levels. See the full breakdown here.Pharmacokinetics (PK)MZE782 demonstrated a favorable plasma PK profi ...